ATRT Research Update

Lantern Pharma Inc. (Nasdaq: LTRN)'s drug candidate, LP-184 shows promising in-vivo activity in Atypical Teratoid Rhabdoid Tumors at 2025 Society for Neuro-Oncology Pediatric Conference.

Independent research from Johns Hopkins Medicine, presented by Dr. Eric Raabe at the 2025 SNO Pediatric Neuro-Oncology Conference, supports Lantern’s data that led to their FDA Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 for the treatment of ATRT.

In-Vivo Data Highlights:

• In-vivo mice models, CHLA06 and BT37, showed survival of increases of 345% and 44% respectively.

• Potent anti-tumor activity across multiple ATRT subtypes (MYC, TYR, SHH)

• Strong blood-brain barrier penetration (Cmax: 730 nM)

• Increased apoptosis(programmed cell death), reduced proliferation in ATRT cancer cells

• Significant survival benefit in two orthotopic xenograft models

• No observed toxicity in vivo

These findings support the planned pediatric clinical trial of LP-184 expected to begin in late 2025 or early 2026.

View the full press release: https://bit.ly/4jrJqF8

Live Interview with Dr. Trisha Larkin

https://www.youtube.com/watch?v=oQNafjKZPy8

Dr. Trisha Larkin is dual-board certified in Pediatrics and Pediatric Hematology-Oncology with an expertise in Pediatric Neuro-Oncology. She serves as the Director of Pediatric Neuro-Oncology at St. Joseph’s Children’s Hospital in Tampa, FL.

Dr. Larkin’s career is dedicated towards expanding clinical growth, research, and clinical trial offerings for children battling central nervous system tumors. Dr. Larkin earned her medical degree from Florida International University in Miami, followed by a Master of Business Administration with a focus in healthcare. She completed her postdoctoral pediatric training at Nicklaus Children’s Hospital, followed by a fellowship in pediatric hematology-oncology and bone marrow transplantation at the University of Florida in Gainesville. She then completed an advanced fellowship in Pediatric Neuro-oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee where she worked on a team of world-renowned physicians and researchers to care for children diagnosed with complex brain and spinal tumors.

Dr. Larkin is passionate about discovering innovative strategies to improve the care of children with brain tumors. Her research interests include early-phase clinical trials and drug development. Dr. Larkin has presented her research in pediatric central nervous system tumors at national and international meetings across the states as well as in Karuizawa, Japan and Hamburg, Germany. Dr. Larkin has published numerous peer-reviewed articles in prestigious journals such as the Journal of Clinical Oncologyand Neuro-Oncology. She serves as associate editor for Neuro-Oncology on the MedNet, an interactive platform for physicians around the world to gather insight about treating complex oncologic diagnoses. She is a member of the American Society of Pediatric Hematology-Oncology, Society for Neuro-Oncology, Children’s Oncology Group, Society for Pediatric Research, American Society of Clinical Oncology, and American Academy of Pediatrics.

Brain Tumor Awareness Month - Lantern Pharma Collaboration

We are excited to announce that this week, we will be collaborating with Lantern Pharma for #BrainTumorAwarenessMonth in an effort to continue our mission of spreading awareness and information about ATRT.

We recently met Lantern at the American Association for Cancer Research (AACR) annual meeting where we learned about their commitment to supporting the ATRT cancer community and how they are using AI to help develop novel drugs for ATRT and other pediatric brain cancers. Learn more about Lantern by visiting their website LanternPharma.com or vising their social channels Lantern Pharma Inc | LinkedIn & @LanternPharma | Twitter

---

[Video] ATRT Facts

https://video.wixstatic.com/video/74712a_5dad46d7a133400193f9c6b60ac204bb/720p/mp4/file.mp4

---

[Video] Drug Facts

Did you know – There have been NO drugs developed and approved specifically to treat malignant pediatric brain tumors like ATRT?

An urgent and unmet need is for the development of safe and effective cancer treatment options.

Lantern and their subsidiary Starlight Therapeutics are committed to shifting the narrative for drug development for pediatric brain tumor patients. One way they are doing this is by leveraging AI to help develop novel and effective therapies to help create meaningful change for these patients.

https://video.wixstatic.com/video/74712a_e9874b7e4fba4e12bf32e1fe8fbb43f7/720p/mp4/file.mp4

---

Zion's courageous battle gives us the drive to make a difference for the next child.

...

Today we are sharing the Angel story of Zion Yamoah, the son of Hope4ATRT Foundation founders, to honor his legacy and to support all the other incredible children who are fighting battles with ATRT.

His story reminds us of the challenges that ATRT patients face and the importance of our efforts to develop therapies to help fight this very rare and aggressive #braintumor.

Learn more about Zion’s story and the Yamoah family’s journey at: https://youtu.be/EVQt1drb7kQ

https://video.wixstatic.com/video/74712a_d1ecbe28bd824e2f844606d5b5722899/720p/mp4/file.mp4